HSV as a vector in vaccine development and gene therapy

The very deep knowledge acquired on the genetics and molecular biology of herpes simplex virus (HSV), major human pathogen whose lifestyle is based on a long-term dual interaction with the infected host characterized by the existence of lytic and latent infections, has allowed the development of potential vectors for several applications in human healthcare. These include delivery and expression of human genes to cells of the nervous system, selective destruction of cancer cells, prophylaxis against infection with HSV or other infectious diseases and targeted infection of specific tissues or organs. Three different classes of vectors can be derived from HSV-1: replication-competent attenuated vectors, replication-incompetent recombinant vectors and defective helper-dependent vectors known as amplicons. This chapter highlights the current knowledge concerning design, construction and recent applications, as well as the potential and current limitations of the three different classes of HSV-1-based vectors.

[1]  S. Nomoto,et al.  The potential of oncolytic virus therapy for pancreatic cancer , 2005, Cancer Gene Therapy.

[2]  J. Glorioso,et al.  Delivery using herpes simplex virus: an overview. , 2004, Methods in molecular biology.

[3]  P. Grandi,et al.  Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. , 2006, Vaccine.

[4]  D. Cory-Slechta,et al.  Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus. , 2000, Human gene therapy.

[5]  D. Knipe,et al.  Construction, Phenotypic Analysis, and Immunogenicity of a UL5/UL29 Double Deletion Mutant of Herpes Simplex Virus 2 , 2000, Journal of Virology.

[6]  David M. Knipe,et al.  Vaccine Protection against Simian Immunodeficiency Virus by Recombinant Strains of Herpes Simplex Virus , 2000, Journal of Virology.

[7]  D. Leib,et al.  Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis , 1995, Journal of virology.

[8]  C. Strathdee,et al.  An Enhanced Packaging System for Helper-Dependent Herpes Simplex Virus Vectors , 1998, Journal of Virology.

[9]  A. Epstein,et al.  Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors. , 2002, The Journal of general virology.

[10]  P. Scardino,et al.  Oncolytic viral gene therapy for prostate cancer using two attenuated, replication‐competent, genetically engineered herpes simplex viruses , 2002, The Prostate.

[11]  S. Brooke,et al.  Over‐expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults , 2003, Journal of neurochemistry.

[12]  D. Kirn,et al.  Oncolytic Viruses: Methods and Protocols , 1972, Nature.

[13]  W. Heiss,et al.  Imaging-guided gene therapy of experimental gliomas. , 2007, Cancer research.

[14]  E. Tyminski,et al.  An infectious transfer and expression system for genomic DNA loci in human and mouse cells , 2001, Nature Biotechnology.

[15]  R. Manservigi,et al.  Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors , 2000, Trends in Neurosciences.

[16]  Lingxin Kong,et al.  Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease , 2005, Brain Research.

[17]  H. Federoff,et al.  Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. , 2002, Cancer research.

[18]  N. DeLuca,et al.  Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0. , 1999, Virology.

[19]  S. Straus,et al.  Herpesvirus vaccines. Development, controversies, and applications. , 1999, Infectious disease clinics of North America.

[20]  D. Bernstein,et al.  Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations. , 2000, Antiviral research.

[21]  R. Martuza,et al.  Oncolytic herpes simplex virus therapy for peripheral nerve tumors. , 2007, Neurosurgical focus.

[22]  S. Moriuchi,et al.  Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. , 1998, Cancer research.

[23]  P. Kennedy,et al.  Molecular biology of herpes simplex virus type 1 latency in the nervous system , 1993, Molecular Neurobiology.

[24]  J. Cohen,et al.  Comparative Efficacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea Pigs , 2005, Journal of Virology.

[25]  N. DeLuca,et al.  Development and application of herpes simplex virus vectors for human gene therapy. , 1995, Annual review of microbiology.

[26]  R. Weissleder,et al.  In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  P. Ryan,et al.  Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". , 1995, Human gene therapy.

[28]  R. Longnecker,et al.  In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. , 1988, The Journal of infectious diseases.

[29]  J. Naegele,et al.  Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase , 1994, Science.

[30]  Ralph Weissleder,et al.  Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo , 2003, Oncogene.

[31]  S. Sabbioni,et al.  Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA , 2007, Gene Therapy.

[32]  R. Manservigi,et al.  Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth , 2007, Cancer Gene Therapy.

[33]  G. Seelig,et al.  Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system , 1996, Journal of virology.

[34]  Bernard Roizman.  HSV gene functions: what have we learned that could be generally applicable to its near and distant cousins? , 1999, Acta virologica.

[35]  I. Mohr,et al.  Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene , 1997, Journal of virology.

[36]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[37]  G. Cheng,et al.  Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2alpha dephosphorylation by the gamma(1)34.5 protein. , 2005, Journal of virology.

[38]  Kaplitt,et al.  Viral Vectors for Gene Delivery and Expression in the CNS , 1996, Methods.

[39]  M. Halterman,et al.  A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  A. Jacobs,et al.  Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  R. Vile,et al.  Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. , 1993, Cancer research.

[42]  S. Inglis,et al.  An efficient selection system for packaging herpes simplex virus amplicons. , 1998, The Journal of general virology.

[43]  P. Scardino,et al.  Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. , 2000, The Journal of urology.

[44]  J. B. Cohen,et al.  HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma , 2000, Gene Therapy.

[45]  M. D'Angelica,et al.  Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production , 2000, Cancer Gene Therapy.

[46]  M. Halterman,et al.  Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). , 1999, Human gene therapy.

[47]  A. Jacobs,et al.  Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. , 2000, Human gene therapy.

[48]  E. Berto,et al.  Development and application of replication-incompetent HSV-1-based vectors , 2005, Gene Therapy.

[49]  B. Roizman,et al.  In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). , 1990, The Journal of infectious diseases.

[50]  I. Mohr,et al.  A Herpes Simplex Virus Type 1 γ34.5 Second-Site Suppressor Mutant That Exhibits Enhanced Growth in Cultured Glioblastoma Cells Is Severely Attenuated in Animals , 2001, Journal of Virology.

[51]  A. Epstein,et al.  Characterization of regulatory functions of the HSV-1 immediate-early protein ICP22. , 1996, Virology.

[52]  N. DeLuca,et al.  Persistence and Expression of the Herpes Simplex Virus Genome in the Absence of Immediate-Early Proteins , 1998, Journal of Virology.

[53]  M. Woodle,et al.  In Vivo Application of RNA Interference: From Functional Genomics to Therapeutics , 2005, Advances in Genetics.

[54]  J. Scharf,et al.  Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. , 1994, Gene therapy.

[55]  R. Martuza,et al.  Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. , 2001, Neoplasia.

[56]  L. Soroceanu,et al.  Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. , 1997, Cancer research.

[57]  S. Nishiguchi,et al.  Structures of replacement vectors for efficient gene targeting. , 1994, Journal of biochemistry.

[58]  S. Brown,et al.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival , 2004, Gene Therapy.

[59]  B. Roizman,et al.  Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. , 1990, Science.

[60]  R. Rees,et al.  Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes. , 2000, Cancer research.

[61]  O. Isacson,et al.  Effect of exogenous nerve growth factor on neurotoxicity of and neuronal gene delivery by a herpes simplex amplicon vector in the rat brain. , 1994, Human gene therapy.

[62]  Erwin G. Van Meir,et al.  Replicative oncolytic herpes simplex viruses in combination cancer therapies. , 2004, Current gene therapy.

[63]  Andrew Freese,et al.  An HSV‐1 Vector Expressing Tyrosine Hydroxylase Causes Production and Release of l‐DOPA from Cultured Rat Striatal Cells , 1995, Journal of neurochemistry.

[64]  R. Vile,et al.  Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. , 2001, Critical reviews in oncology/hematology.

[65]  I. Mohr,et al.  Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Markert,et al.  Oncolytic HSV-1 for the treatment of brain tumours. , 2006, Herpes : the journal of the IHMF.

[67]  R. Martuza,et al.  Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates , 1999, Journal of Virology.

[68]  J. Markert,et al.  Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. B. Cohen,et al.  Connexin 43-enhanced suicide gene therapy using herpesviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[70]  Z. Ram,et al.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells , 1997, Nature Medicine.

[71]  P. Lam,et al.  Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. , 2007, Human gene therapy.

[72]  R. Rouse,et al.  Rapid method for construction of recombinant HSV gene transfer vectors , 1997, Gene Therapy.

[73]  S. Korsching,et al.  The neurotrophic factor concept: a reexamination , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[74]  B. Roizman,et al.  Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins , 2007, Proceedings of the National Academy of Sciences.

[75]  R. Sapolsky,et al.  Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects , 1995, Journal of Neuroscience Methods.

[76]  T. Pawlik,et al.  Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene , 2002, Cancer.

[77]  J. Glorioso,et al.  Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. , 2002, Diabetes.

[78]  E. Chiocca,et al.  The effect of ganciclovir on herpes simplex virus-mediated oncolysis. , 1997, The Journal of surgical research.

[79]  A. Epstein,et al.  Gene Transfer of NMDAR1 Subunit Sequences to the Rat CNS Using Herpes Simplex Virus Vectors Interfered with Habituation , 2002, Cellular and Molecular Neurobiology.

[80]  B Roizman,et al.  The nine ages of herpes simplex virus. , 2001, Herpes : the journal of the IHMF.

[81]  R. Ramakrishnan,et al.  Deletion of multiple immediate–early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons , 1998, Gene Therapy.

[82]  M. Ranasinghe,et al.  Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells , 2004, Gene Therapy.

[83]  B. Roizman,et al.  The diversity and unity of Herpesviridae. , 1991, Comparative immunology, microbiology and infectious diseases.

[84]  S. Advani,et al.  Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[85]  L. Kaiser,et al.  Herpes simplex 1716--an ICP 34.5 mutant--is severely replication restricted in human skin xenografts in vivo. , 1996, Virology.

[86]  N. DeLuca,et al.  Relationship of herpes simplex virus genome configuration to productive and persistent infections , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[87]  L. Corey,et al.  Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research , 2003, Clinical Microbiology Reviews.

[88]  D. Pfaff,et al.  Specific Patterns of Defective HSV-1 Gene Transfer in the Adult Central Nervous System: Implications for Gene Targeting , 1994, Experimental Neurology.

[89]  R. Martuza,et al.  In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. , 2001, Cancer research.

[90]  T. Pawlik,et al.  Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. , 2001, Cancer research.

[91]  K. Nakano,et al.  HSV trafficking and development of gene therapy vectors with applications in the nervous system , 2005, Gene Therapy.

[92]  P. Grandi,et al.  HSV-1 virions engineered for specific binding to cell surface receptors. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[93]  R. Spaete,et al.  Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. , 1998, The Journal of infectious diseases.

[94]  V. Hukkanen,et al.  Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. , 2005, Current gene therapy.

[95]  S. Inglis,et al.  Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. , 1995, The Journal of infectious diseases.

[96]  X. Breakefield,et al.  Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. , 2003, Methods in molecular medicine.

[97]  B. Sodeik,et al.  Herpes simplex virus type 1 infection of polarized epithelial cells requires microtubules and access to receptors present at cell-cell contact sites. , 2004, The Journal of general virology.

[98]  H. Huynh,et al.  An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[99]  W. Heiss,et al.  Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. , 2003, Human gene therapy.

[100]  K. Shah,et al.  HSV amplicon vectors for cancer therapy. , 2006, Current gene therapy.

[101]  P. Lam,et al.  Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration. , 2007, Journal of virological methods.

[102]  S. Dewhurst,et al.  Amplicons as vaccine vectors. , 2006, Current gene therapy.

[103]  L D Lunsford,et al.  Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[104]  G. Comi,et al.  Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach , 2000, Journal of Neuroimmunology.

[105]  P. Lam,et al.  Targeting proliferating tumor cells via the transcriptional control of therapeutic genes , 2006, Cancer Gene Therapy.

[106]  D. Benos,et al.  Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[107]  Y. Kawaguchi,et al.  Identification of Proteins Phosphorylated Directly by the Us3 Protein Kinase Encoded by Herpes Simplex Virus 1 , 2005, Journal of Virology.

[108]  J. Bertino,et al.  Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi‐mutated herpes simplex virus type‐1 (G207) , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  X. Breakefield,et al.  Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors ‡ , 2002, The journal of gene medicine.

[110]  W. Jarnagin,et al.  Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses , 2000, Journal of Gastrointestinal Surgery.

[111]  J. Markert,et al.  Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins , 1998, Gene Therapy.

[112]  R. D. Wiley,et al.  Expression of Human Immunodeficiency Virus Type 1 gp120 from Herpes Simplex Virus Type 1-Derived Amplicons Results in Potent, Specific, and Durable Cellular and Humoral Immune Responses , 2002, Journal of Virology.

[113]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[114]  K. Tsumoto,et al.  Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[115]  W. Herr,et al.  DNA Recognition by the Herpes Simplex Virus Transactivator VP16: a Novel DNA-Binding Structure , 2001, Molecular and Cellular Biology.

[116]  R. Desrosiers,et al.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. , 2007, Virology.

[117]  Robert E. White,et al.  Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene , 2000, Nature Biotechnology.

[118]  J. Subak-Sharpe,et al.  Hsv Molecular Biology: General Aspects of Herpes Simplex Virus Molecular Biology , 2004, Virus Genes.

[119]  R. Martuza,et al.  Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[120]  K. Tanabe,et al.  Viral oncolysis. , 2002, The oncologist.

[121]  X. Breakefield,et al.  Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. , 1998, Journal of the National Cancer Institute.

[122]  A. Barzilai,et al.  The Herpes Simplex Virus Type 1 vhs-UL41 Gene Secures Viral Replication by Temporarily Evading Apoptotic Cellular Response to Infection: Vhs-UL41 Activity Might Require Interactions with Elements of Cellular mRNA Degradation Machinery , 2006, Journal of Virology.

[123]  J. B. Cohen,et al.  Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model , 2002, Gene Therapy.

[124]  A. Epstein,et al.  HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. , 2005, Current gene therapy.

[125]  E. Chiocca,et al.  Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[126]  B. Roizman,et al.  The UL13 protein kinase and the infected cell type are determinants of posttranslational modification of ICP0. , 1997, Virology.

[127]  S. McMahon,et al.  The Glial Cell Line-Derived Neurotrophic Factor Family Receptor Components Are Differentially Regulated within Sensory Neurons after Nerve Injury , 2000, The Journal of Neuroscience.

[128]  K. Dobberstein,et al.  New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. , 1998, Human gene therapy.

[129]  R. Herman,et al.  The herpes simplex virus type 1 ICP6 gene is regulated by a 'leaky' early promoter. , 1992, Virus research.

[130]  A. Epstein,et al.  A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus. , 2001, Human gene therapy.

[131]  S. Ylä-Herttuala,et al.  Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. , 2000, Human gene therapy.

[132]  J. Glorioso,et al.  Pseudotyping of Glycoprotein D-Deficient Herpes Simplex Virus Type 1 with Vesicular Stomatitis Virus Glycoprotein G Enables Mutant Virus Attachment and Entry , 2000, Journal of Virology.

[133]  R. Reichman.  Herpes simplex virus infections , 1984, European Journal of Clinical Microbiology.

[134]  R. Coffin,et al.  Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo , 2004, Gene Therapy.

[135]  P. Stricklett,et al.  Site-specific recombination using an epitope tagged bacteriophage P1 Cre recombinase. , 1998, Gene.

[136]  A. Kudoh,et al.  Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10. , 2006, Journal of virological methods.

[137]  K. Delman,et al.  Combination Vascular Delivery of Herpes Simplex Oncolytic Viruses and Amplicon Mediated Cytokine Gene Transfer Is Effective Therapy for Experimental Liver Cancer , 2001, Molecular medicine.

[138]  H. Neumann,et al.  Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[139]  H. Federoff,et al.  Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma , 2004, Journal of Gastrointestinal Surgery.

[140]  B. Rouse,et al.  Herpes simplex virus latency and the immune response. , 1998, Current opinion in microbiology.

[141]  G. Holmes,et al.  Enhanced auditory reversal learning by genetic activation of protein kinase C in small groups of rat hippocampal neurons. , 2001, Brain research. Molecular brain research.

[142]  C. Fraefel,et al.  Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia , 2005, Gene Therapy.

[143]  L. Stanberry.  Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. , 2004, Herpes : the journal of the IHMF.

[144]  A. Epstein.  HSV-1-based amplicon vectors: design and applications , 2005, Gene Therapy.

[145]  J. Glorioso,et al.  Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. , 2006, Gene therapy.

[146]  D. Andrews,et al.  Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. , 1996, The EMBO journal.

[147]  C. Brandt,et al.  Herpes simplex virus-mediated gene delivery to the rodent visual system. , 2000, Investigative ophthalmology & visual science.

[148]  M. Hamon,et al.  Therapeutic Efficacy in Experimental Polyarthritis of Viral-Driven Enkephalin Overproduction in Sensory Neurons , 2001, The Journal of Neuroscience.

[149]  L. Morrison,et al.  Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. , 2001, Virology.

[150]  T. Daikoku,et al.  Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells. , 1991, The Journal of general virology.

[151]  T. Friedmann,et al.  Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1 , 1992, Journal of virology.

[152]  F. Cosset,et al.  Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors , 1997, Journal of virology.

[153]  J. Markert,et al.  Genetically engineered human herpes simplex virus in the treatment of brain tumours. , 2001, Herpes : the journal of the IHMF.

[154]  M. D'Angelica,et al.  In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors , 1999, Cancer Immunology, Immunotherapy.

[155]  E. Burton,et al.  Gene therapy progress and prospects: Parkinson's disease , 2003, Gene Therapy.

[156]  D. Busch,et al.  Protection from Bacterial Infection by a Single Vaccination with Replication-Deficient Mutant Herpes Simplex Virus Type 1 , 2004, Journal of Virology.

[157]  R. Vile,et al.  Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[158]  M. Kaplitt,et al.  Defective viral vectors as agents for gene transfer in the nervous system , 1997, Journal of Neuroscience Methods.

[159]  M. Chao.  Trophic factors: An evolutionary cul‐de‐sac or door into higher neuronal function? , 2000, Journal of neuroscience research.

[160]  R. Manservigi,et al.  HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens. , 2006, Viral immunology.

[161]  C. Fraefel,et al.  HSV-1 amplicon vectors--simplicity and versatility. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[162]  H. Federoff,et al.  Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival , 2007, Brain Research.

[163]  D. Leib,et al.  Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. , 1998, Vaccine.

[164]  A. Epstein,et al.  Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. , 2005, The Journal of general virology.

[165]  A. Kwong,et al.  Minireview: the herpes simplex virus amplicon--a versatile defective virus vector. , 1994, Gene therapy.

[166]  R. Coffin,et al.  ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties , 2003, Gene Therapy.

[167]  B. Roizman,et al.  Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[168]  B. Roizman.  The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[169]  O. Wildner,et al.  Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer , 2006, Gene Therapy.

[170]  J. Weir,et al.  Incorporation of a lambda phage recombination system and EGFP detection to simplify mutagenesis of Herpes simplex virus bacterial artificial chromosomes , 2007, BMC biotechnology.

[171]  D. Goldstein,et al.  Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector. , 2003, Human gene therapy.

[172]  R. Everett.  ICP0, a regulator of herpes simplex virus during lytic and latent infection. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[173]  J. Glorioso,et al.  Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[174]  L. Soroceanu,et al.  Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[175]  R. Manservigi,et al.  Molecular analysis of behavior by gene transfer into neurons with herpes simplex vectors 1 Published on the World Wide Web on 5 March 1999. 1 , 1999, Brain Research.

[176]  A. Jacobs,et al.  Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. , 1997, Human gene therapy.

[177]  P. Kaufman,et al.  Herpes simplex virus mediated gene transfer to primate ocular tissues. , 1999, Experimental eye research.

[178]  D. Kondziolka,et al.  Gene transfer to glial tumors using herpes simplex virus. , 2004, Methods in molecular biology.

[179]  S. Kuriyama,et al.  Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma , 1995, Hepatology.

[180]  X. Breakefield,et al.  Prodrug activation enzymes in cancer gene therapy , 2000, The journal of gene medicine.

[181]  Ajay Niranjan,et al.  Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[182]  M. D. De Angelis,et al.  A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. , 2005, Human molecular genetics.

[183]  D. Alsop,et al.  Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. , 1995, Virology.

[184]  J. Shah,et al.  Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. , 2001, Human gene therapy.

[185]  P. Rennie,et al.  An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells , 2007, Cancer Gene Therapy.

[186]  R. Lachmann,et al.  Herpes simplex virus‐based vectors , 2004, International journal of experimental pathology.

[187]  B. Roizman.  Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective. , 1991, Reviews of infectious diseases.

[188]  P. Lam,et al.  Glioma-specific and cell cycle-regulated herpes simplex virus type 1 amplicon viral vector. , 2004, Human gene therapy.

[189]  C. Hartnick,et al.  Defective HSV-1 vector expressing BDNF in auditory ganglia elicits neurite outgrowth: model for treatment of neuron loss following cochlear degeneration. , 1996, Human gene therapy.

[190]  Xiaoliu Zhang,et al.  Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer , 2004, The Prostate.

[191]  D. Bernstein,et al.  Herpes simplex virus vaccines. , 1999, Vaccine.

[192]  L. Aurelian.  HSV-induced apoptosis in herpes encephalitis. , 2005, Current topics in microbiology and immunology.

[193]  B. Roizman,et al.  Processing of the herpes simplex virus regulatory protein alpha 22 mediated by the UL13 protein kinase determines the accumulation of a subset of alpha and gamma mRNAs and proteins in infected cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[194]  J. Shah,et al.  Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector. , 1998, American journal of surgery.

[195]  B Roizman,et al.  Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. , 1999, Cancer research.

[196]  B. Roizman,et al.  The Second-Site Mutation in the Herpes Simplex Virus Recombinants Lacking the γ134.5 Genes Precludes Shutoff of Protein Synthesis by Blocking the Phosphorylation of eIF-2α , 1998, Journal of Virology.

[197]  T. Pawlik,et al.  Regulation of Herpes Simplex Virus 1 Replication Using Tumor-Associated Promoters , 2002, Annals of surgery.

[198]  A. Epstein,et al.  Hippocampal infection with HSV‐1‐derived vectors expressing an NMDAR1 antisense modifies behavior , 2003, Genes, brain, and behavior.

[199]  X. Breakefield,et al.  Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. , 1999, Cancer research.

[200]  C. Fraefel,et al.  Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. , 1998, Human gene therapy.

[201]  S. Mohan,et al.  HSV-1 amplicon-mediated transfer of 128-kb BMP-2 genomic locus stimulates osteoblast differentiation in vitro. , 2004, Biochemical and biophysical research communications.

[202]  O. Wildner,et al.  Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment , 2007, Cancer Gene Therapy.

[203]  E. Petersen,et al.  Herpes simplex viruses. , 2009 .

[204]  D. Knipe,et al.  Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity , 2002, Journal of Virology.

[205]  J. Glorioso,et al.  Replication-defective genomic HSV gene therapy vectors: design, production and CNS applications. , 2005, Current opinion in molecular therapeutics.

[206]  B. Paradiso,et al.  Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo , 2005, Gene Therapy.

[207]  R. Martuza,et al.  In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. , 1998, Journal of immunology.

[208]  Y. Becker,et al.  Effect of herpes simplex virus type-1 UL41 gene on the stability of mRNA from the cellular genes: β-actin, fibronectin, glucose transporter-1, and docking protein, and on virus intraperitoneal pathogenicity to newborn mice , 1993, Virus Genes.

[209]  C. Lilley,et al.  Development and Optimization of Herpes Simplex Virus Vectors for Multiple Long-Term Gene Delivery to the Peripheral Nervous System , 2000, Journal of Virology.

[210]  R. Sapolsky,et al.  Overexpression of HSP72 after Induction of Experimental Stroke Protects Neurons from Ischemic Damage , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[211]  M. Halterman,et al.  Improved HSV‐1 amplicon packaging using virion host shutoff mutants lacking mRNAse activity , 2006, The journal of gene medicine.

[212]  J. Garrido,et al.  Defining Responsiveness of Avian Cochlear Neurons to Brain‐Derived Neurotrophic Factor and Nerve Growth Factor by HSV‐1‐Mediated Gene Transfer , 1998, Journal of neurochemistry.

[213]  N. Markovitz,et al.  Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[214]  F. Moolten,et al.  Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. , 1990, Journal of the National Cancer Institute.

[215]  Y. Kawaguchi,et al.  Construction of an Excisable Bacterial Artificial Chromosome Containing a Full-Length Infectious Clone of Herpes Simplex Virus Type 1: Viruses Reconstituted from the Clone Exhibit Wild-Type Properties In Vitro and In Vivo , 2003, Journal of Virology.

[216]  James N. Davis,et al.  BCL-2 Transduction, Using a Herpes Simplex Virus Amplicon, Protects Hippocampal Neurons from Transient Global Ischemia , 1999, Experimental Neurology.

[217]  R. Martuza,et al.  Flip-Flop HSV-BAC: Bacterial Artificial Chromosome Based System for Rapid Generation of Recombinant Herpes Simplex Virus Vectors Using Two Independent Site-specific Recombinases , 2006 .

[218]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[219]  C. Fraefel,et al.  In vivo gene transfer to the rat retina using herpes simplex virus type 1 (HSV-1)-based amplicon vectors , 2005, Gene Therapy.

[220]  H. Federoff,et al.  HSV vector-mediated gene delivery to the central nervous system. , 2001, Current opinion in molecular therapeutics.

[221]  M. Tsukuda,et al.  Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma. , 2000, Cancer letters.

[222]  C. Link,et al.  Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir , 2002, Cancer Gene Therapy.

[223]  David L. Zimmerman,et al.  Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS. , 2006, Journal of virological methods.

[224]  N. DeLuca,et al.  Activation of immediate-early, early, and late promoters by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4 , 1985, Molecular and cellular biology.

[225]  J. Yewdell,et al.  Herpes simplex virus turns off the TAP to evade host immunity , 1995, Nature.

[226]  C. Lilley,et al.  Deletion of the Virion Host Shutoff Protein (vhs) from Herpes Simplex Virus (HSV) Relieves the Viral Block to Dendritic Cell Activation: Potential of vhs− HSV Vectors for Dendritic Cell-Mediated Immunotherapy , 2003, Journal of Virology.

[227]  C. Fraefel,et al.  BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[228]  R. Weichselbaum,et al.  Genetically engineered HSV in the treatment of glioma: a review , 2000, Reviews in medical virology.

[229]  S. Landolfo,et al.  The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. , 2004, Experimental cell research.

[230]  R. Spaete,et al.  Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. , 2005, Vaccine.

[231]  H. Federoff,et al.  Herpes Simplex Virus Amplicon Delivery of a Hypoxia-Inducible Soluble Vascular Endothelial Growth Factor Receptor (sFlk-1) Inhibits Angiogenesis and Tumor Growth in Pancreatic Adenocarcinoma , 2005, Annals of Surgical Oncology.

[232]  L. Aurelian,et al.  Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). , 1999, Vaccine.

[233]  R. F. Cook,et al.  The Active Site of ICP47, a Herpes Simplex Virus–encoded Inhibitor of the Major Histocompatibility Complex (MHC)-encoded Peptide Transporter Associated with Antigen Processing (TAP), Maps to the NH2-terminal 35 Residues , 1997, The Journal of experimental medicine.

[234]  X. Breakefield,et al.  HSV-1 amplicon vectors. , 2002, Methods in enzymology.

[235]  H. H. Wu,et al.  Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion , 2001, Gene Therapy.

[236]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[237]  B. Roizman,et al.  The herpes simplex virus 1 gene for ICP34.5, which maps in inverted repeats, is conserved in several limited-passage isolates but not in strain 17syn+ , 1990, Journal of virology.

[238]  An efficient in vivo recombination cloning procedure for modifying and combining HSV-1 cosmids. , 1999, Journal of virological methods.

[239]  J. Glorioso,et al.  Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. , 2004, Annual review of microbiology.

[240]  P. Grandi,et al.  Targeting HSV amplicon vectors. , 2004, Methods.

[241]  Simon C Watkins,et al.  Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22 , 1996, Journal of virology.

[242]  P. Schaffer,et al.  ICP22 and the UL13 Protein Kinase Are both Required for Herpes Simplex Virus-Induced Modification of the Large Subunit of RNA Polymerase II , 1999, Journal of Virology.

[243]  R. Rouse,et al.  Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications , 1998, Gene Therapy.

[244]  R. Weissleder,et al.  Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. , 2004, Cancer research.

[245]  H. Wakimoto,et al.  Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models , 2006, Gene Therapy.

[246]  N. DeLuca,et al.  The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27 , 1997, Journal of virology.

[247]  Yaming Wang,et al.  Helper Virus-Free Herpes Simplex Virus-1 Plasmid Vectors for Gene Therapy of Parkinson's Disease and Other Neurological Disorders , 1997, Experimental Neurology.

[248]  R. Martuza,et al.  Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. , 1999, Human gene therapy.

[249]  T. Ndung’u,et al.  Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. , 2007, Virology.

[250]  R. Ramakrishnan,et al.  Replication-defective herpes simplex virus vectors for gene transfer in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.